Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Hypoxia-inducible factor-1 (HIF-1) signaling is crucial in tumorigenesis, impacting tumor growth and metastasis.
• Overexpression of HIF-1α, a key mediator of hypoxic response, correlates with poor prognosis in solid cancers.
• Targeting HIF-1 pathways is a promising strategy for cancer therapy, with natural products as potential sources of inhibitors.

Purpose of the Study:

• To provide bio-pharmacological considerations for selecting natural compounds as HIF-1 inhibitors.
• To accelerate the development of novel anti-cancer drugs targeting the HIF-1 pathway.
• To highlight the importance of assessing cancer dependency on HIF1A for identifying suitable disease models.

Main Methods:

• Review of existing literature on HIF-1 signaling and natural product-derived inhibitors.
• Analysis of bio-pharmacological criteria for natural compound selection.
• Discussion on the role of HIF1A dependency in cancer model selection.

Main Results:

• Preclinical efforts to develop HIF-1 inhibitors from natural products have not yet yielded clinically approved treatments.
• Natural products represent a rich reservoir for novel therapeutic agents targeting cancer.
• Identifying specific cancer types dependent on HIF1A is crucial for effective drug development.

Conclusions:

• Strategic selection of natural compounds based on bio-pharmacological insights can advance HIF-1 inhibitor development.
• Assessing cancer-specific HIF1A dependency is key to establishing relevant preclinical models.
• This approach may lead to potent, targeted therapies derived from natural products for various cancer types.